By Counterforce Health Team in Cresemba (isavuconazole) —

Myths vs. Facts: Getting Cresemba (Isavuconazole) Covered by Aetna (CVS Health) in Illinois - Complete Appeals Guide

Answer Box: Getting Cresemba Covered by Aetna in Illinois

Cresemba (isavuconazole) requires prior authorization from Aetna (CVS Health) in Illinois. You'll need documented invasive aspergillosis or mucormycosis, evidence of voriconazole failure/intolerance for aspergillosis cases, and typically an infectious disease specialist consultation. If denied, Illinois provides strong appeal rights including binding external review through the Illinois Department of Insurance within 4 months of denial.

First step today: Have your doctor verify your exact Aetna formulary status and download the plan-specific Cresemba PA form through CVS Caremark.

Table of Contents

Why Myths About Cresemba Coverage Persist

Specialty antifungal coverage generates confusion because the stakes are high and the approval process involves multiple layers. Patients facing invasive fungal infections often receive conflicting information from different sources—pharmacy staff who see only formulary status, clinic staff unfamiliar with prior authorization requirements, and even well-meaning advocates who don't understand payer-specific policies.

Illinois patients have particularly strong appeal rights that many don't know about. The state's external review process has a 46% overturn rate for denials, yet many patients give up after the first denial without using these protections.

Understanding the facts—rather than assumptions—about Aetna's Cresemba coverage can save weeks of delays and prevent dangerous gaps in treatment.

Common Myths vs. Facts

Myth 1: "If my doctor prescribes Cresemba, Aetna has to cover it"

Fact: Aetna requires prior authorization for Cresemba across most plans. Even with a valid prescription, coverage depends on meeting specific clinical criteria including documented invasive fungal infection and, for aspergillosis cases, evidence that voriconazole failed or caused intolerance.

Myth 2: "Aetna automatically denies expensive specialty drugs"

Fact: Aetna's 2024 data shows denial rates around 22% for in-network services. Many Cresemba denials are overturned on appeal when proper documentation is provided, particularly with infectious disease specialist support.

Myth 3: "I need to try every other antifungal first"

Fact: Aetna's step therapy for Cresemba typically requires only voriconazole trial/failure for invasive aspergillosis. For mucormycosis, Cresemba may be approved as first-line when amphotericin B is contraindicated, per FDA labeling.

Myth 4: "Appeals take months and rarely work"

Fact: Illinois requires Aetna to decide internal appeals within 15 business days for standard cases, 24 hours for urgent cases. External review through Illinois DOI typically resolves within 30 days with binding decisions.

Myth 5: "Only infectious disease doctors can prescribe Cresemba"

Fact: While many Aetna policies prefer ID specialist involvement, other specialists (hematology/oncology, transplant medicine) can prescribe with appropriate documentation of the clinical scenario.

Myth 6: "Generic alternatives work just as well"

Fact: There are no generic versions of isavuconazole. The relevant comparison is with other antifungals like voriconazole or amphotericin B, each with different safety profiles and resistance patterns that justify Cresemba in specific clinical situations.

Myth 7: "External review is expensive and complicated"

Fact: Illinois external review is free to consumers and uses simple forms. The state pays all costs, and decisions are binding on insurers.

Myth 8: "If Aetna denies Cresemba, I have to pay full price"

Fact: Cresemba Support Solutions provides PA assistance and appeal support. Additionally, patient assistance programs may be available while appeals are pending.

What Actually Influences Approval

Clinical Documentation Requirements

Aetna's Cresemba approval depends on specific clinical criteria documented in your medical records:

Diagnosis Evidence:

  • Confirmed or probable invasive aspergillosis or mucormycosis
  • Supporting microbiology (cultures, PCR, histopathology)
  • Imaging showing invasive disease
  • Relevant ICD-10 codes (B44.x for aspergillosis, B46.x for mucormycosis)

Prior Therapy Documentation:

  • For aspergillosis: Voriconazole trial with documented failure (persistent/progressive disease) or intolerance (hepatotoxicity, neurotoxicity, visual disturbances)
  • Specific dates, doses, and outcomes of prior treatments
  • Laboratory evidence supporting toxicity claims (liver enzymes, ECGs)

Risk Factor Assessment:

  • Immunocompromised status (transplant, neutropenia, high-dose steroids)
  • Contraindications to alternative therapies
  • Drug interaction concerns with formulary options

Administrative Factors

Prescriber Credentials: While not always required, infectious disease specialist involvement significantly improves approval rates.

Submission Quality: Complete PA forms with all requested attachments prevent "incomplete information" denials that delay treatment.

Timing: Urgent cases with proper medical justification can receive expedited review within 72 hours.

Avoid These Preventable Mistakes

1. Submitting Incomplete Prior Authorization Forms

The Problem: Missing clinical notes, lab results, or imaging reports trigger automatic denials for "insufficient information."

The Fix: Use Cresemba Support Solutions to verify all required documents before submission. Create a checklist including: PA form, prescriber notes, ID consultation, microbiology results, imaging reports, and prior therapy documentation.

2. Inadequate Documentation of Voriconazole Issues

The Problem: Stating "patient failed voriconazole" without specifics leads to denials.

The Fix: Document exact dates, doses, duration, and specific outcomes. For failure: "Persistent fevers and progressive pulmonary nodules on CT after 14 days of voriconazole 4mg/kg q12h." For intolerance: "AST/ALT elevated to 8x ULN within 5 days; discontinued due to hepatotoxicity."

3. Missing Urgent Appeal Deadlines

The Problem: Treating all appeals as standard when clinical urgency exists.

The Fix: Request expedited review when delay could worsen outcomes. Document medical urgency: "Patient in ICU with progressive invasive aspergillosis; delay in effective antifungal therapy may result in respiratory failure."

4. Giving Up After First Denial

The Problem: Accepting initial denials without understanding Illinois appeal rights.

The Fix: Illinois provides multiple appeal levels with high success rates. File internal appeal within 30 days, then external review if needed.

5. Not Engaging State Resources

The Problem: Struggling alone instead of using Illinois consumer assistance.

The Fix: Contact the Illinois Department of Insurance Office of Consumer Health Insurance at 877-527-9431 for guidance on appeal rights and external review processes.

Quick Action Plan: Three Steps to Take Today

Step 1: Verify Your Exact Coverage Status

Patient Action: Log into your Aetna member portal or call member services to confirm:

  • Cresemba's formulary tier on your specific plan
  • Prior authorization requirements
  • Any quantity limits or site-of-care restrictions

Provider Action: Check the Aetna 2025 Precertification List and obtain your plan's specific Cresemba PA form.

Step 2: Gather Essential Documentation

Create a complete file including:

  • Current infectious disease consultation notes
  • Microbiology and imaging supporting invasive fungal infection diagnosis
  • Detailed prior antifungal treatment history with outcomes
  • Laboratory results showing toxicity from previous therapies
  • Current clinical status and treatment urgency level

Step 3: Submit Strategic Prior Authorization

If you're the prescriber: Complete the PA emphasizing medical necessity, prior therapy failures, and specialist involvement. Mark as urgent if clinically appropriate.

If you're the patient: Ensure your care team has contacted Cresemba Support Solutions for PA assistance and benefits verification.

Everyone: Document submission with confirmation numbers and track response timelines.

Illinois-Specific Appeal Rights

Illinois residents have among the strongest insurance appeal protections in the United States, particularly valuable for specialty medications like Cresemba.

Internal Appeal Process

After an Aetna denial, you have 180 days to file an internal appeal. Aetna must:

  • Acknowledge your appeal within 3 business days
  • Request any additional information needed within 3 business days
  • Issue a decision within 15 business days (standard) or 24 hours (urgent)

External Review Rights

If Aetna upholds the denial on internal appeal, Illinois provides binding external review:

Timeline: Request within 4 months of final internal denial Cost: Free to consumers Process: Independent physician reviewer with relevant specialty expertise Decision Time: 5 business days after all materials received Outcome: Binding on Aetna if overturned

From Our Advocates: We've seen several Illinois patients successfully overturn Cresemba denials through external review by providing comprehensive infectious disease consultation notes and clear documentation of voriconazole intolerance. The key was organizing medical records to directly address each criterion in Aetna's policy. These cases typically resolved within 6-8 weeks from initial denial to coverage approval.

Consumer Assistance Resources

Illinois Department of Insurance: 877-527-9431 for appeal guidance and external review assistance

Illinois Attorney General Health Care Helpline: 1-877-305-5145 for complex cases requiring regulatory intervention

Resources and Support

Manufacturer Support

Cresemba Support Solutions provides:

  • Benefits verification and PA form assistance
  • Appeal support and status tracking
  • Clinical resources for prescribers

Illinois State Resources

Clinical Guidelines

At Counterforce Health, we help patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals through targeted, evidence-backed strategies. Our platform analyzes denial letters, plan policies, and clinical notes to draft point-by-point rebuttals that align with payer requirements and maximize approval chances.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance policies vary by plan and change frequently. Always verify current requirements with your specific Aetna plan and consult healthcare professionals for medical decisions. For personalized assistance with Cresemba coverage issues, contact the Illinois Department of Insurance or Counterforce Health for specialized appeal support.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.